skmel5 melanoma cell line Search Results


skmel5 cell lines  (ATCC)
99
ATCC skmel5 cell lines
Figure 2 GPC-3.CAR/sIL-15 Vδ1 T cells exert robust in vitro antitumor activity against GPC-3-expressing tumor cell lines even in the presence of soluble GPC-3. (A) GPC-3.CAR Vδ1 (red), GPC-3.CAR/sIL-15 Vδ1 (blue), NT.CAR/sIL15 (non-targeting control CAR with soluble IL-15) Vδ1 (green) or untransduced (UT) Vδ1 (purple) were cocultured with RFluc-expressing GPC-3+ HepG2 and PLC/PRF/5 (PLC) liver cancer cell lines (top panels) or GPC-3- <t>SKMEL5</t> and HCT116 melanoma and colon cancer cell lines (bottom panels) across listed E:T ratios for ~18-hour. Data shown as mean±SEM of duplicates and represent two banks for each construct. (B) Cytotoxic potential of GPC-3.CAR/sIL-15 Vδ1 T cells against HepG2 and PLC cells at a fixed 1:1 ratio was assessed in the presence of soluble GPC-3 (0.3 μg/mL-20 μg/mL) in an 18 hours cytotoxicity assay. Per cent inhibition was calculated relative to the T cell alone control. Data shown as mean±SEM of triplicates and represent two banks. (C, D) Cytokine production by GPC-3.CAR/sIL-15 and GPC-3.CAR Vδ1 T cell effectors after a 24 hours co-culture with HepG2 cells (C) or PLC cells (D) at 2:1 E:T ratio. Data shown as mean±SEM of triplicates and represent two banks. For (A–D), controls included Vδ1 T cells and tumor cell lines cultured alone. Except for (tumor necrosis factor alpha) TNF-α (2 pg/mL from PLC), no cytokines were detected from either tumor cell. P values were calculated using two-way analysis of variance with Tukey post hoc *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. CAR, chimeric antigen receptor; GPC-3, glypican-3; ns, not significant, sIL-15, secreted interleukin-15.
Skmel5 Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/skmel5+melanoma+cell+line/HCT+116/pm34916256-52-4-10
Average 99 stars, based on 1 article reviews
skmel5 cell lines - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
skmel 5  (ATCC)
96
ATCC skmel 5
Figure 2 GPC-3.CAR/sIL-15 Vδ1 T cells exert robust in vitro antitumor activity against GPC-3-expressing tumor cell lines even in the presence of soluble GPC-3. (A) GPC-3.CAR Vδ1 (red), GPC-3.CAR/sIL-15 Vδ1 (blue), NT.CAR/sIL15 (non-targeting control CAR with soluble IL-15) Vδ1 (green) or untransduced (UT) Vδ1 (purple) were cocultured with RFluc-expressing GPC-3+ HepG2 and PLC/PRF/5 (PLC) liver cancer cell lines (top panels) or GPC-3- <t>SKMEL5</t> and HCT116 melanoma and colon cancer cell lines (bottom panels) across listed E:T ratios for ~18-hour. Data shown as mean±SEM of duplicates and represent two banks for each construct. (B) Cytotoxic potential of GPC-3.CAR/sIL-15 Vδ1 T cells against HepG2 and PLC cells at a fixed 1:1 ratio was assessed in the presence of soluble GPC-3 (0.3 μg/mL-20 μg/mL) in an 18 hours cytotoxicity assay. Per cent inhibition was calculated relative to the T cell alone control. Data shown as mean±SEM of triplicates and represent two banks. (C, D) Cytokine production by GPC-3.CAR/sIL-15 and GPC-3.CAR Vδ1 T cell effectors after a 24 hours co-culture with HepG2 cells (C) or PLC cells (D) at 2:1 E:T ratio. Data shown as mean±SEM of triplicates and represent two banks. For (A–D), controls included Vδ1 T cells and tumor cell lines cultured alone. Except for (tumor necrosis factor alpha) TNF-α (2 pg/mL from PLC), no cytokines were detected from either tumor cell. P values were calculated using two-way analysis of variance with Tukey post hoc *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. CAR, chimeric antigen receptor; GPC-3, glypican-3; ns, not significant, sIL-15, secreted interleukin-15.
Skmel 5, supplied by ATCC, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/skmel5+melanoma+cell+line/SK-MEL-5/pmc02668260-60-10-32
Average 96 stars, based on 1 article reviews
skmel 5 - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
transfection human melanoma lines  (ATCC)
99
ATCC transfection human melanoma lines
Figure 2 GPC-3.CAR/sIL-15 Vδ1 T cells exert robust in vitro antitumor activity against GPC-3-expressing tumor cell lines even in the presence of soluble GPC-3. (A) GPC-3.CAR Vδ1 (red), GPC-3.CAR/sIL-15 Vδ1 (blue), NT.CAR/sIL15 (non-targeting control CAR with soluble IL-15) Vδ1 (green) or untransduced (UT) Vδ1 (purple) were cocultured with RFluc-expressing GPC-3+ HepG2 and PLC/PRF/5 (PLC) liver cancer cell lines (top panels) or GPC-3- <t>SKMEL5</t> and HCT116 melanoma and colon cancer cell lines (bottom panels) across listed E:T ratios for ~18-hour. Data shown as mean±SEM of duplicates and represent two banks for each construct. (B) Cytotoxic potential of GPC-3.CAR/sIL-15 Vδ1 T cells against HepG2 and PLC cells at a fixed 1:1 ratio was assessed in the presence of soluble GPC-3 (0.3 μg/mL-20 μg/mL) in an 18 hours cytotoxicity assay. Per cent inhibition was calculated relative to the T cell alone control. Data shown as mean±SEM of triplicates and represent two banks. (C, D) Cytokine production by GPC-3.CAR/sIL-15 and GPC-3.CAR Vδ1 T cell effectors after a 24 hours co-culture with HepG2 cells (C) or PLC cells (D) at 2:1 E:T ratio. Data shown as mean±SEM of triplicates and represent two banks. For (A–D), controls included Vδ1 T cells and tumor cell lines cultured alone. Except for (tumor necrosis factor alpha) TNF-α (2 pg/mL from PLC), no cytokines were detected from either tumor cell. P values were calculated using two-way analysis of variance with Tukey post hoc *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. CAR, chimeric antigen receptor; GPC-3, glypican-3; ns, not significant, sIL-15, secreted interleukin-15.
Transfection Human Melanoma Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/skmel5+melanoma+cell+line/A-375/pmc04571945-85-3-19
Average 99 stars, based on 1 article reviews
transfection human melanoma lines - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
cultures human melanoma cell lines  (ATCC)
97
ATCC cultures human melanoma cell lines
Figure 2 GPC-3.CAR/sIL-15 Vδ1 T cells exert robust in vitro antitumor activity against GPC-3-expressing tumor cell lines even in the presence of soluble GPC-3. (A) GPC-3.CAR Vδ1 (red), GPC-3.CAR/sIL-15 Vδ1 (blue), NT.CAR/sIL15 (non-targeting control CAR with soluble IL-15) Vδ1 (green) or untransduced (UT) Vδ1 (purple) were cocultured with RFluc-expressing GPC-3+ HepG2 and PLC/PRF/5 (PLC) liver cancer cell lines (top panels) or GPC-3- <t>SKMEL5</t> and HCT116 melanoma and colon cancer cell lines (bottom panels) across listed E:T ratios for ~18-hour. Data shown as mean±SEM of duplicates and represent two banks for each construct. (B) Cytotoxic potential of GPC-3.CAR/sIL-15 Vδ1 T cells against HepG2 and PLC cells at a fixed 1:1 ratio was assessed in the presence of soluble GPC-3 (0.3 μg/mL-20 μg/mL) in an 18 hours cytotoxicity assay. Per cent inhibition was calculated relative to the T cell alone control. Data shown as mean±SEM of triplicates and represent two banks. (C, D) Cytokine production by GPC-3.CAR/sIL-15 and GPC-3.CAR Vδ1 T cell effectors after a 24 hours co-culture with HepG2 cells (C) or PLC cells (D) at 2:1 E:T ratio. Data shown as mean±SEM of triplicates and represent two banks. For (A–D), controls included Vδ1 T cells and tumor cell lines cultured alone. Except for (tumor necrosis factor alpha) TNF-α (2 pg/mL from PLC), no cytokines were detected from either tumor cell. P values were calculated using two-way analysis of variance with Tukey post hoc *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. CAR, chimeric antigen receptor; GPC-3, glypican-3; ns, not significant, sIL-15, secreted interleukin-15.
Cultures Human Melanoma Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/skmel5+melanoma+cell+line/A2058/pmc08599733-73-3-20
Average 97 stars, based on 1 article reviews
cultures human melanoma cell lines - by Bioz Stars, 2026-10
97/100 stars
  Buy from Supplier
human melanoma cell lines  (ATCC)
95
ATCC human melanoma cell lines
Figure 2 GPC-3.CAR/sIL-15 Vδ1 T cells exert robust in vitro antitumor activity against GPC-3-expressing tumor cell lines even in the presence of soluble GPC-3. (A) GPC-3.CAR Vδ1 (red), GPC-3.CAR/sIL-15 Vδ1 (blue), NT.CAR/sIL15 (non-targeting control CAR with soluble IL-15) Vδ1 (green) or untransduced (UT) Vδ1 (purple) were cocultured with RFluc-expressing GPC-3+ HepG2 and PLC/PRF/5 (PLC) liver cancer cell lines (top panels) or GPC-3- <t>SKMEL5</t> and HCT116 melanoma and colon cancer cell lines (bottom panels) across listed E:T ratios for ~18-hour. Data shown as mean±SEM of duplicates and represent two banks for each construct. (B) Cytotoxic potential of GPC-3.CAR/sIL-15 Vδ1 T cells against HepG2 and PLC cells at a fixed 1:1 ratio was assessed in the presence of soluble GPC-3 (0.3 μg/mL-20 μg/mL) in an 18 hours cytotoxicity assay. Per cent inhibition was calculated relative to the T cell alone control. Data shown as mean±SEM of triplicates and represent two banks. (C, D) Cytokine production by GPC-3.CAR/sIL-15 and GPC-3.CAR Vδ1 T cell effectors after a 24 hours co-culture with HepG2 cells (C) or PLC cells (D) at 2:1 E:T ratio. Data shown as mean±SEM of triplicates and represent two banks. For (A–D), controls included Vδ1 T cells and tumor cell lines cultured alone. Except for (tumor necrosis factor alpha) TNF-α (2 pg/mL from PLC), no cytokines were detected from either tumor cell. P values were calculated using two-way analysis of variance with Tukey post hoc *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. CAR, chimeric antigen receptor; GPC-3, glypican-3; ns, not significant, sIL-15, secreted interleukin-15.
Human Melanoma Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/skmel5+melanoma+cell+line/MeWo%3B+Melanoma%3B+Human/pmc08599733-145-0-16
Average 95 stars, based on 1 article reviews
human melanoma cell lines - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier
braf-mutant melanoma cell line mmacsf  (BioResource International Inc)
90
BioResource International Inc braf-mutant melanoma cell line mmacsf
Figure 2 GPC-3.CAR/sIL-15 Vδ1 T cells exert robust in vitro antitumor activity against GPC-3-expressing tumor cell lines even in the presence of soluble GPC-3. (A) GPC-3.CAR Vδ1 (red), GPC-3.CAR/sIL-15 Vδ1 (blue), NT.CAR/sIL15 (non-targeting control CAR with soluble IL-15) Vδ1 (green) or untransduced (UT) Vδ1 (purple) were cocultured with RFluc-expressing GPC-3+ HepG2 and PLC/PRF/5 (PLC) liver cancer cell lines (top panels) or GPC-3- <t>SKMEL5</t> and HCT116 melanoma and colon cancer cell lines (bottom panels) across listed E:T ratios for ~18-hour. Data shown as mean±SEM of duplicates and represent two banks for each construct. (B) Cytotoxic potential of GPC-3.CAR/sIL-15 Vδ1 T cells against HepG2 and PLC cells at a fixed 1:1 ratio was assessed in the presence of soluble GPC-3 (0.3 μg/mL-20 μg/mL) in an 18 hours cytotoxicity assay. Per cent inhibition was calculated relative to the T cell alone control. Data shown as mean±SEM of triplicates and represent two banks. (C, D) Cytokine production by GPC-3.CAR/sIL-15 and GPC-3.CAR Vδ1 T cell effectors after a 24 hours co-culture with HepG2 cells (C) or PLC cells (D) at 2:1 E:T ratio. Data shown as mean±SEM of triplicates and represent two banks. For (A–D), controls included Vδ1 T cells and tumor cell lines cultured alone. Except for (tumor necrosis factor alpha) TNF-α (2 pg/mL from PLC), no cytokines were detected from either tumor cell. P values were calculated using two-way analysis of variance with Tukey post hoc *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. CAR, chimeric antigen receptor; GPC-3, glypican-3; ns, not significant, sIL-15, secreted interleukin-15.
Braf Mutant Melanoma Cell Line Mmacsf, supplied by BioResource International Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/skmel5+melanoma+cell+line/braf+mutant+melanoma+cell+line+mmacsf/bio_rxiv__2021__12__06__471514-153-30-47
Average 90 stars, based on 1 article reviews
braf-mutant melanoma cell line mmacsf - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier
skmel 5 cell lines  (Selleck Chemicals)
96
Selleck Chemicals skmel 5 cell lines
Figure 2 GPC-3.CAR/sIL-15 Vδ1 T cells exert robust in vitro antitumor activity against GPC-3-expressing tumor cell lines even in the presence of soluble GPC-3. (A) GPC-3.CAR Vδ1 (red), GPC-3.CAR/sIL-15 Vδ1 (blue), NT.CAR/sIL15 (non-targeting control CAR with soluble IL-15) Vδ1 (green) or untransduced (UT) Vδ1 (purple) were cocultured with RFluc-expressing GPC-3+ HepG2 and PLC/PRF/5 (PLC) liver cancer cell lines (top panels) or GPC-3- <t>SKMEL5</t> and HCT116 melanoma and colon cancer cell lines (bottom panels) across listed E:T ratios for ~18-hour. Data shown as mean±SEM of duplicates and represent two banks for each construct. (B) Cytotoxic potential of GPC-3.CAR/sIL-15 Vδ1 T cells against HepG2 and PLC cells at a fixed 1:1 ratio was assessed in the presence of soluble GPC-3 (0.3 μg/mL-20 μg/mL) in an 18 hours cytotoxicity assay. Per cent inhibition was calculated relative to the T cell alone control. Data shown as mean±SEM of triplicates and represent two banks. (C, D) Cytokine production by GPC-3.CAR/sIL-15 and GPC-3.CAR Vδ1 T cell effectors after a 24 hours co-culture with HepG2 cells (C) or PLC cells (D) at 2:1 E:T ratio. Data shown as mean±SEM of triplicates and represent two banks. For (A–D), controls included Vδ1 T cells and tumor cell lines cultured alone. Except for (tumor necrosis factor alpha) TNF-α (2 pg/mL from PLC), no cytokines were detected from either tumor cell. P values were calculated using two-way analysis of variance with Tukey post hoc *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. CAR, chimeric antigen receptor; GPC-3, glypican-3; ns, not significant, sIL-15, secreted interleukin-15.
Skmel 5 Cell Lines, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/skmel5+melanoma+cell+line/Vemurafenib/pmc06422198-225-7-14
Average 96 stars, based on 1 article reviews
skmel 5 cell lines - by Bioz Stars, 2026-10
96/100 stars
  Buy from Supplier
cancer  (ATCC)
99
ATCC cancer
Figure 2 GPC-3.CAR/sIL-15 Vδ1 T cells exert robust in vitro antitumor activity against GPC-3-expressing tumor cell lines even in the presence of soluble GPC-3. (A) GPC-3.CAR Vδ1 (red), GPC-3.CAR/sIL-15 Vδ1 (blue), NT.CAR/sIL15 (non-targeting control CAR with soluble IL-15) Vδ1 (green) or untransduced (UT) Vδ1 (purple) were cocultured with RFluc-expressing GPC-3+ HepG2 and PLC/PRF/5 (PLC) liver cancer cell lines (top panels) or GPC-3- <t>SKMEL5</t> and HCT116 melanoma and colon cancer cell lines (bottom panels) across listed E:T ratios for ~18-hour. Data shown as mean±SEM of duplicates and represent two banks for each construct. (B) Cytotoxic potential of GPC-3.CAR/sIL-15 Vδ1 T cells against HepG2 and PLC cells at a fixed 1:1 ratio was assessed in the presence of soluble GPC-3 (0.3 μg/mL-20 μg/mL) in an 18 hours cytotoxicity assay. Per cent inhibition was calculated relative to the T cell alone control. Data shown as mean±SEM of triplicates and represent two banks. (C, D) Cytokine production by GPC-3.CAR/sIL-15 and GPC-3.CAR Vδ1 T cell effectors after a 24 hours co-culture with HepG2 cells (C) or PLC cells (D) at 2:1 E:T ratio. Data shown as mean±SEM of triplicates and represent two banks. For (A–D), controls included Vδ1 T cells and tumor cell lines cultured alone. Except for (tumor necrosis factor alpha) TNF-α (2 pg/mL from PLC), no cytokines were detected from either tumor cell. P values were calculated using two-way analysis of variance with Tukey post hoc *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. CAR, chimeric antigen receptor; GPC-3, glypican-3; ns, not significant, sIL-15, secreted interleukin-15.
Cancer, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/skmel5+melanoma+cell+line/PC-3/10__1002_slash_jhet__4552-117-22-29
Average 99 stars, based on 1 article reviews
cancer - by Bioz Stars, 2026-10
99/100 stars
  Buy from Supplier
human cell lines  (DSMZ)
95
DSMZ human cell lines
Figure 2 GPC-3.CAR/sIL-15 Vδ1 T cells exert robust in vitro antitumor activity against GPC-3-expressing tumor cell lines even in the presence of soluble GPC-3. (A) GPC-3.CAR Vδ1 (red), GPC-3.CAR/sIL-15 Vδ1 (blue), NT.CAR/sIL15 (non-targeting control CAR with soluble IL-15) Vδ1 (green) or untransduced (UT) Vδ1 (purple) were cocultured with RFluc-expressing GPC-3+ HepG2 and PLC/PRF/5 (PLC) liver cancer cell lines (top panels) or GPC-3- <t>SKMEL5</t> and HCT116 melanoma and colon cancer cell lines (bottom panels) across listed E:T ratios for ~18-hour. Data shown as mean±SEM of duplicates and represent two banks for each construct. (B) Cytotoxic potential of GPC-3.CAR/sIL-15 Vδ1 T cells against HepG2 and PLC cells at a fixed 1:1 ratio was assessed in the presence of soluble GPC-3 (0.3 μg/mL-20 μg/mL) in an 18 hours cytotoxicity assay. Per cent inhibition was calculated relative to the T cell alone control. Data shown as mean±SEM of triplicates and represent two banks. (C, D) Cytokine production by GPC-3.CAR/sIL-15 and GPC-3.CAR Vδ1 T cell effectors after a 24 hours co-culture with HepG2 cells (C) or PLC cells (D) at 2:1 E:T ratio. Data shown as mean±SEM of triplicates and represent two banks. For (A–D), controls included Vδ1 T cells and tumor cell lines cultured alone. Except for (tumor necrosis factor alpha) TNF-α (2 pg/mL from PLC), no cytokines were detected from either tumor cell. P values were calculated using two-way analysis of variance with Tukey post hoc *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. CAR, chimeric antigen receptor; GPC-3, glypican-3; ns, not significant, sIL-15, secreted interleukin-15.
Human Cell Lines, supplied by DSMZ, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/skmel5+melanoma+cell+line/U-266/pm18181098-44-1-33
Average 95 stars, based on 1 article reviews
human cell lines - by Bioz Stars, 2026-10
95/100 stars
  Buy from Supplier

Image Search Results


Figure 2 GPC-3.CAR/sIL-15 Vδ1 T cells exert robust in vitro antitumor activity against GPC-3-expressing tumor cell lines even in the presence of soluble GPC-3. (A) GPC-3.CAR Vδ1 (red), GPC-3.CAR/sIL-15 Vδ1 (blue), NT.CAR/sIL15 (non-targeting control CAR with soluble IL-15) Vδ1 (green) or untransduced (UT) Vδ1 (purple) were cocultured with RFluc-expressing GPC-3+ HepG2 and PLC/PRF/5 (PLC) liver cancer cell lines (top panels) or GPC-3- SKMEL5 and HCT116 melanoma and colon cancer cell lines (bottom panels) across listed E:T ratios for ~18-hour. Data shown as mean±SEM of duplicates and represent two banks for each construct. (B) Cytotoxic potential of GPC-3.CAR/sIL-15 Vδ1 T cells against HepG2 and PLC cells at a fixed 1:1 ratio was assessed in the presence of soluble GPC-3 (0.3 μg/mL-20 μg/mL) in an 18 hours cytotoxicity assay. Per cent inhibition was calculated relative to the T cell alone control. Data shown as mean±SEM of triplicates and represent two banks. (C, D) Cytokine production by GPC-3.CAR/sIL-15 and GPC-3.CAR Vδ1 T cell effectors after a 24 hours co-culture with HepG2 cells (C) or PLC cells (D) at 2:1 E:T ratio. Data shown as mean±SEM of triplicates and represent two banks. For (A–D), controls included Vδ1 T cells and tumor cell lines cultured alone. Except for (tumor necrosis factor alpha) TNF-α (2 pg/mL from PLC), no cytokines were detected from either tumor cell. P values were calculated using two-way analysis of variance with Tukey post hoc *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. CAR, chimeric antigen receptor; GPC-3, glypican-3; ns, not significant, sIL-15, secreted interleukin-15.

Journal: Journal for immunotherapy of cancer

Article Title: Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.

doi: 10.1136/jitc-2021-003441

Figure Lengend Snippet: Figure 2 GPC-3.CAR/sIL-15 Vδ1 T cells exert robust in vitro antitumor activity against GPC-3-expressing tumor cell lines even in the presence of soluble GPC-3. (A) GPC-3.CAR Vδ1 (red), GPC-3.CAR/sIL-15 Vδ1 (blue), NT.CAR/sIL15 (non-targeting control CAR with soluble IL-15) Vδ1 (green) or untransduced (UT) Vδ1 (purple) were cocultured with RFluc-expressing GPC-3+ HepG2 and PLC/PRF/5 (PLC) liver cancer cell lines (top panels) or GPC-3- SKMEL5 and HCT116 melanoma and colon cancer cell lines (bottom panels) across listed E:T ratios for ~18-hour. Data shown as mean±SEM of duplicates and represent two banks for each construct. (B) Cytotoxic potential of GPC-3.CAR/sIL-15 Vδ1 T cells against HepG2 and PLC cells at a fixed 1:1 ratio was assessed in the presence of soluble GPC-3 (0.3 μg/mL-20 μg/mL) in an 18 hours cytotoxicity assay. Per cent inhibition was calculated relative to the T cell alone control. Data shown as mean±SEM of triplicates and represent two banks. (C, D) Cytokine production by GPC-3.CAR/sIL-15 and GPC-3.CAR Vδ1 T cell effectors after a 24 hours co-culture with HepG2 cells (C) or PLC cells (D) at 2:1 E:T ratio. Data shown as mean±SEM of triplicates and represent two banks. For (A–D), controls included Vδ1 T cells and tumor cell lines cultured alone. Except for (tumor necrosis factor alpha) TNF-α (2 pg/mL from PLC), no cytokines were detected from either tumor cell. P values were calculated using two-way analysis of variance with Tukey post hoc *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. CAR, chimeric antigen receptor; GPC-3, glypican-3; ns, not significant, sIL-15, secreted interleukin-15.

Article Snippet: HepG2, PLC/PRF/5, HCT116 and SKMEL5 cell lines were purchased from ATCC (Manassas, Virginia).

Techniques: In Vitro, Activity Assay, Expressing, Control, Construct, Cytotoxicity Assay, Inhibition, Co-Culture Assay, Cell Culture